Literature DB >> 17316606

The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation.

Lothar Faerber1, Sabine Drechsler, Stephan Ladenburger, Harald Gschaidmeier, Wolfgang Fischer.   

Abstract

The 5-HT3 receptor is a pentameric ligand-gated cation channel which is found in the central and peripheral nervous system and on extraneuronal locations like lymphocytes, monocytes and fetal tissue. Five monomer subtypes, the 5-HT(3A-E) subunits, have been identified which show differences in the amino-terminal and the transmembrane region. The functional relevance of different receptor compositions is not yet clarified. 5-HT3 receptors are located predominantly in CNS regions that are involved in the integration of the vomiting reflex, pain processing, the reward system and anxiety control. The preferential localization on nerve endings is consistent with a physiological role of 5-HT3 receptors in the control of neurotransmitter release such as dopamine, cholecystokinin, glutamate, acetylcholine, GABA, substance P, or serotonin itself. 5-HT3-receptor agonists cause unpleasant effects like nausea and anxiety, and no clinical use has been considered. In contrast, the introduction of 5-HT3-receptor antagonists for chemotherapy-induced vomiting was extremely successful. After development of other gastrointestinal indications like postoperative vomiting and diarrhea-predominant irritable bowel syndrome recent research focuses on rheumatological indications such as fibromyalgia, rheumatoid arthritis and tendinopathies. Positive effects have also been observed for pain syndromes such as chronic neuropathic pain and migraine. These effects seem to be related to substance P-mediated inflammation and hyperalgesia. Furthermore, antiinflammatory and immunomodulatory properties have been observed for 5-HT3-receptor antagonists which might explain promising findings in systemic sclerosis and other immunological conditions. For all of these innovative indications the optimal dosing schedule is a crucial issue, since a bell-shaped dose-response curve has been observed repeatedly for 5-HT3-receptor antagonists, particularly in CNS effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17316606     DOI: 10.1016/j.ejphar.2007.01.028

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  65 in total

1.  The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome.

Authors:  Lisa A Kilpatrick; Jennifer S Labus; Kristen Coveleskie; Christian Hammer; Gudrun Rappold; Kirsten Tillisch; Joshua A Bueller; Brandall Suyenobu; Johana M Jarcho; Jim A McRoberts; Beate Niesler; Emeran A Mayer
Journal:  Gastroenterology       Date:  2011-03-21       Impact factor: 22.682

2.  Involvement of 5HT3 Receptors in Anti-Inflammatory Effects of Tropisetron on Experimental TNBS-Induced Colitis in Rat.

Authors:  Azadeh Motavallian; Mohsen Minaiyan; Mohammad Rabbani; Sasan Andalib; Parvin Mahzouni
Journal:  Bioimpacts       Date:  2013-06-18

3.  Inhibition of temporomandibular joint input to medullary dorsal horn neurons by 5HT3 receptor antagonist in female rats.

Authors:  K Okamoto; A Katagiri; M Rahman; R Thompson; D A Bereiter
Journal:  Neuroscience       Date:  2015-04-23       Impact factor: 3.590

4.  Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.

Authors:  Stefano Pallanti; Silvia Bernardi; Sarah Antonini; Nikhilesh Singh; Eric Hollander
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

5.  Effects of Palonosetron, a 5-HT3 Receptor Antagonist, on Mechanical Allodynia in a Rat Model of Postoperative Pain.

Authors:  Ki Tae Jung; Myung Ha Yoon; Hyun Young Lee; Bo Yeon Yu; Dong Kyu Kim; Kyung Joon Lim
Journal:  Korean J Pain       Date:  2013-04-03

Review 6.  TNF-alpha and neuropathic pain--a review.

Authors:  Lawrence Leung; Catherine M Cahill
Journal:  J Neuroinflammation       Date:  2010-04-16       Impact factor: 8.322

7.  Synthesis and evaluation of (S)-[(18)F]fesetron in the rat brain as a potential PET imaging agent for serotonin 5-HT3 receptors.

Authors:  Neema K Pithia; Christopher Liang; Xiang-Zuo Pan; Min-Liang Pan; Jogeshwar Mukherjee
Journal:  Bioorg Med Chem Lett       Date:  2016-03-08       Impact factor: 2.823

8.  Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests.

Authors:  Yeshwant Kurhe; Mahesh Radhakrishnan; Deepali Gupta
Journal:  Metab Brain Dis       Date:  2014-06-27       Impact factor: 3.584

9.  The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1.

Authors:  Liuliang Qin; Dezheng Zhao; Jianfeng Xu; Xianghui Ren; Ernest F Terwilliger; Sareh Parangi; Jack Lawler; Harold F Dvorak; Huiyan Zeng
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

10.  Brn3a regulates neuronal subtype specification in the trigeminal ganglion by promoting Runx expression during sensory differentiation.

Authors:  Iain M Dykes; Jason Lanier; S Raisa Eng; Eric E Turner
Journal:  Neural Dev       Date:  2010-01-22       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.